Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (7941)	5/8/2000 11:43:00 PM
From: Vector1	Read Replies (2) \| Respond to of 9719

Spec. Thanks for the info on Biochem. Lot's to look at. I think Robinson at LGND is more interested in empire building than shareholder value. Of course I am a former shareholder who lost money on the stock. Yes CELG is overweighted but why do you think the valuation is too high. I beleive Thalomid will be a $400m oncology drug and with Novartis behind them Attendade will dominate the Ritalin market. IMO Greenspan will either raise 25bps or will raise 50bps and signal no more increases. V1